The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,022
Mishima, S., Kawazoe, A., Nakamura, Y., Sasaki, A., Kotani, D., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Ohtsu, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0514-3 · Cited by 145
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 156
Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice
Harlander, S., Schönenberger, D., Toussaint, N. C., Prummer, M., Catalano, A., Brandt, L., Moch, H., Wild, P. J., & Frew, I. J. (2017) · Nature Medicine · doi:10.1038/nm.4343 · Cited by 143
Chowdhury, N., & Drake, C. G. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.07.009 · Cited by 149
Vano, Y. A., Elaidi, R., Bennamoun, M., Chevreau, C., Borchiellini, D., Pannier, D., Maillet, D., Gross‐Goupil, M., Tournigand, C., Laguerre, B., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00128-0 · Cited by 151
Miyamoto, S., Kakutani, S., Sato, Y., Hanashi, A., Kinoshita, Y., & Ishikawa, A. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy053 · Cited by 142
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
van Willigen, W. W., Bloemendal, M., Gerritsen, W. R., Schreibelt, G., de Vries, I. J. M., & Bol, K. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02265 · Cited by 145
The intimate relationship between gut microbiota and cancer immunotherapy
Elkrief, A., Derosa, L., Zitvogel, L., Kroemer, G., & Routy, B. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1527167 · Cited by 143
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
Hilmi, M., Jouinot, A., Burns, R. G., Pigneur, F., Mounier, R., Gondin, J., Neuzillet, C., & Goldwasser, F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.003 · Cited by 145
d’Izarny-Gargas, T., Dürrbach, A., & Zaidan, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15811 · Cited by 144
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 144
Wang, M., Zhai, X., Li, J., Guan, J., Xu, S., Li, Y., & Zhu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670391 · Cited by 143
on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0579-z · Cited by 140
Self-citationZaid, H. B., Parker, W. P., Safdar, N. S., Gershman, B., Erwin, P. J., Murad, M. H., Boorjian, S. A., Costello, B. A., Thompson, R. H., & Leibovich, B. C. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.07.079 · Cited by 140
Pal, S. K., Sonpavde, G., Agarwal, N., Vogelzang, N. J., Srinivas, S., Haas, N. B., Signoretti, S., McGregor, B. A., Jones, J. O., Lanman, R. B., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.046 · Cited by 140
Self-citationGauci, M.-L., Lanoy, É., Champiat, S., Caramella, C., Ammari, S., Aspeslagh, S., Varga, A., Baldini, C., Bahleda, R., Gazzah, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0793 · Cited by 142
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 145
Self-citationNatural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Kelly, M. J., Michie, J., Pijpers, L., Johnstone, R. W., Kearney, C. J., & Oliaro, J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.017 · Cited by 140
Lussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 142
Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
Karamchandani, D. M., & Chetty, R. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205143 · Cited by 139
Precision immunoprofiling by image analysis and artificial intelligence
Koelzer, V. H., Sirinukunwattana, K., Rittscher, J., & Mertz, K. D. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2485-z · Cited by 148
Apolo, A. B., Nadal, R., Girardi, D. M., Niglio, S. A., Ley, L., Cordes, L. M., Steinberg, S. M., Ortiz, O. S., Cadena, J., Diaz, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01652 · Cited by 140
Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia
Malaker, S. A., Penny, S. A., Steadman, L. G., Myers, P. T., Loke, J. C. T., Raghavan, M., Bai, D. L., Shabanowitz, J., Hunt, D. F., & Cobbold, M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0280 · Cited by 141
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 141
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
Luen, S. J., Savas, P. S., Fox, S. B., Salgado, R., & Loi, S. (2017) · Pathology · doi:10.1016/j.pathol.2016.10.010 · Cited by 137
Colli, L. M., Machiela, M. J., Myers, T. A., Jessop, L., Yu, K. F., & Chanock, S. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0170 · Cited by 138
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Mahoney, K. M., Shukla, S. A., Patsoukis, N., Chaudhri, A., Browne, E. P., Arazi, A., Eisenhaure, T., Pendergraft, W. F., Hua, P., Pham, H. C., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2282-1 · Cited by 137
Wu, Y., Xu, J., Du, C., Wu, Y., Xia, D., Lv, W., & Hu, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01161 · Cited by 143
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 141
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 140
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 146
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Shiuan, E. F., Beckermann, K. E., Özgün, A., Kelly, C. M., McKean, M. A., McQuade, J. L., Thompson, M. A., Puzanov, I. J., Greer, J. P., Rapisuwon, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0210-0 · Cited by 135
Layer, J. P., Kronmüller, M., Quast, T., Konijnenberg, D., Effern, M., Hinze, D., Althoff, K., Schramm, A. R., Westermann, F., Peifer, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320626 · Cited by 138
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Rassy, E., Flippot, R., & Albiges, L. K. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920907504 · Cited by 136
Targeting the tumor microenvironment in renal cell cancer biology and therapy
Heidegger, I., Pircher, A., & Pichler, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00490 · Cited by 133
Immunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.001 · Cited by 133
Laubli, H. P., Balmelli, C., Kaufmann, L., Stanczak, M. A., Syedbasha, M., Vogt, D., Hertig, A., Müller, B. P., Gautschi, O. P., Stenner, F., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0353-7 · Cited by 133
Tartari, F., Santoni, M., Burattini, L., Mazzanti, P., Onofri, A., & Berardi, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.002 · Cited by 134
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 135
McDermott, D. F., Lee, J., Bjarnason, G. A., Larkin, J., Gafanov, R. A., Kochenderfer, M. D., Jensen, N. V., Donskov, F. N., Malik, J., Poprach, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02363 · Cited by 133
Self-citationBerghoff, A. S., Ricken, G., Wilhelm, D., Rajky, O., Widhalm, G., Dieckmann, K. U., Birner, P., Bartsch, R., & Preusser, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2216-8 · Cited by 131
Judd, J., Zibelman, M. R., Handorf, E. A., O’Neill, J. P., Ramamurthy, C., Bentota, S., Doyle, J., Uzzo, R. G., Bauman, J. R., Borghaei, H., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0133 · Cited by 132
Self-citationKiyota, N., Hasegawa, Y., Takahashi, S., Yokota, T., Yen, C.-J., Iwae, S., Shimizu, Y., Hong, R., Goto, M., Kang, J. H., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.07.023 · Cited by 130
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
McKay, R. R., Bossé, D., Xie, W., Wankowicz, S. A. M., Flaifel, A., Moreira, R. B., Lalani, A. A., Martini, D. J., Wei, X. X., Braun, D. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0475 · Cited by 130
Self-citationESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
Passaro, A., Addeo, A., von Garnier, C., Blackhall, F. H., Planchard, D., Felip, E., Dziadziuszko, R., de Marinis, F., Reck, M., Bouchaab, H., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000820 · Cited by 130
Cheung, P., Patel, S., North, S. A., Sahgal, A., Chu, W., Soliman, H., Ahmad, B., Winquist, E., Niazi, T. M., Patenaude, F., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.07.026 · Cited by 130
Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 130
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Sideras, K., Biermann, K., Verheij, J., Takkenberg, R. B., Mancham, S., Hansen, B. E., Schutz, H. M., de Man, R. A., Sprengers, D., Buschow, S. I., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1273309 · Cited by 130
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 129
IL-2 and Beyond in Cancer Immunotherapy
Wrangle, J. M., Patterson, A., Johnson, C. B., Neitzke, D. J., Mehrotra, S., Denlinger, C. E., Paulos, C. M., Li, Z., Cole, D. J., & Rubinstein, M. P. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0101 · Cited by 132
Ladomersky, E., Scholtens, D. M., Kocherginsky, M., Hibler, E. A., Bartom, E. T., Otto‐Meyer, S., Zhai, L., Lauing, K. L., Choi, J., Sosman, J. A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00200 · Cited by 130
Self-citationHyperprogression under Immunotherapy
Frélaut, M., Tourneau, C. L., & Borcoman, É. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112674 · Cited by 130
Ravi, P. K., Mantia, C. M., Su, C. T., Sorenson, K., Elhag, D., Rathi, N., Bakouny, Z., Agarwal, N., Zakharia, Y., Costello, B. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2169 · Cited by 130
Self-citationCheckpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
Alhamad, T., Venkatachalam, K., Linette, G. P., & Brennan, D. C. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13711 · Cited by 127
Guan, J., Lim, K. S., Mekhail, T. M., & Chang, C.-C. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0361-ra · Cited by 131
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Johnson, R. M. G., & Dong, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00961 · Cited by 131
Guan, X., Zhang, C., Zhao, J., Sun, G., Song, Q., & Jia, W. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.012 · Cited by 128
Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism
Zhu, J., Petit, P.-F., & den Eynde, B. J. V. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2269-y · Cited by 127
Wen, W. X., & Leong, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215381 · Cited by 129
Singla, N., Hutchinson, R. C., Ghandour, R. A., Freifeld, Y. N., Fang, D., Sagalowsky, A. I., Lotan, Y., Bagrodia, A., Margulis, V., Hammers, H. J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.02.029 · Cited by 127
Self-citationO’Malley, D. M., Oaknin, A., Monk, B. J., Selle, F., Rojas, C., Gladieff, L., Berton, D., Leary, A. F., Moore, K. N., Estevez-Diz, M. D. P., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.018 · Cited by 127
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy
Larimer, B. M., Wehrenberg-Klee, E. P., Caraballo, A., & Mahmood, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173930 · Cited by 127
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, M., Yi, M., Li, N., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00211-8 · Cited by 129
Pancreatic Cancer and Immunotherapy: A Clinical Overview
Timmer, F. E. F., Geboers, B., Nieuwenhuizen, S., Dijkstra, M., Schouten, E. A. C., Puijk, R. S., de Vries, J. J. J., van den Tol, M. P., Bruynzeel, A. M. E., Streppel, M. M., et al. (2021) · Cancers · doi:10.3390/cancers13164138 · Cited by 129
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Hirsch, L., Zitvogel, L., Eggermont, A. M. M., & Marabelle, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0294-4 · Cited by 131
Role of immune-checkpoint inhibitors in lung cancer
Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 130
Immunotherapy in advanced gastric cancer, is it the future?
Coutzac, C., Pernot, S., Chaput, N., & Zaanan, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.007 · Cited by 125
MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential
Penticuff, J. C., Woolbright, B. L., Sielecki, T. M., Weir, S. J., & Taylor, J. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0171-9 · Cited by 125
Shah, A. Y., Kotecha, R. R., Lemke, E., Chandramohan, A., Chaim, J. L., Msaouel, P., Xiao, L., Gao, J., Campbell, M. T., Zurita, A. J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.003 · Cited by 125
Self-citationBergerot, P. G., Lamb, P., Wang, E. W., & Pal, S. K. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1399 · Cited by 125
De Novo Malignancies after Kidney Transplantation
Al-Adra, D., Al-Qaoud, T., Fowler, K. J., & Wong, G. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14570920 · Cited by 125
Clinical pharmacology considerations for the development of immune checkpoint inhibitors
Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Abdel-Rahman, O. M., & Fouad, M. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816636557 · Cited by 124
Mori, H., Kubo, M., Yamaguchi, R., Nishimura, R., Osako, T., Arima, N., Okumura, Y., Okido, M., Yamada, M., Kai, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14698 · Cited by 128
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126
Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., Cristofanilli, M., Sosman, J. A., & Giles, F. J. (2017) · Oncotarget · doi:10.18632/oncotarget.13315 · Cited by 123
Self-citationThe expanding role of immunotherapy
Martín-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J. A., & Tabernero, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.008 · Cited by 125
Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 124
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Carneiro, B. A., Konda, B., Costa, R. B., Costa, R. L. B., Sagar, V., Gursel, D. B., Kirschner, L. S., Chae, Y. K., Abdulkadir, S. A., RADEMAKER, A. W., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00600 · Cited by 123
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
Morse, M. A., Höchster, H. S., & Benson, A. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0176 · Cited by 123
Bilen, M. A., Shabto, J. M., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6073-7 · Cited by 126
Integrative clinical and molecular characterization of translocation renal cell carcinoma
Bakouny, Z., Sadagopan, A., Ravi, P. K., Metaferia, N. Y., Li, J., AbuHammad, S., Tang, S., Denize, T., Garner, E. R., Gao, X. Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110190 · Cited by 123
Self-citationInterleukin-10 in cancer immunotherapy: from bench to bedside
Salkeni, M. A., & Naing, A. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.05.003 · Cited by 123
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Naing, A., Wong, D. J. L., Infante, J. R., Korn, W. M., Aljumaily, R. M., Papadopoulos, K. P., Autio, K. A., Pant, S., Bauer, T. M., Drakaki, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30514-5 · Cited by 124
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 130
Yang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12534 · Cited by 124
PD ‐1/ PD ‐L1 inhibitors in haematological malignancies: update 2017
Jelı́nek, T., Mihályová, J., Kaščák, M., Ďuraš, J., & Hájek, R. (2017) · Immunology · doi:10.1111/imm.12788 · Cited by 122
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 122
Computational Prediction and Validation of Tumor-Associated Neoantigens
Roudko, V., Greenbaum, B. D., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 123
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Xu, Y., Song, G., Xie, S., Jiang, W., Chen, X., Chu, M., Hu, X., & Wang, Z. P. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.029 · Cited by 122
Rini, B. I., McDermott, D. F., Hammers, H. J., Bro, W., Bukowski, R. M., Faba, B., Faba, J., Figlin, R. A., Hutson, T. E., Jonasch, E. W., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0180-7 · Cited by 120
Self-citationRitchie, G. E., Gasper, H. M., Man, J., Lord, S. J., Marschner, I. C., Friedlander, M. L., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 121
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Wang, X., Wang, F., Zhong, M., Yarden, Y., & Fu, L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01200-x · Cited by 124
Mou, Y., Wu, J., Zhang, Y., Abdihamid, O., Duan, C., & Li, B. (2021) · BMC Cancer · doi:10.1186/s12885-020-07726-z · Cited by 122
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib, E., Nassar, A. H., Akl, E. W., Alaiwi, S. A., Nuzzo, P. V., Mouhieddine, T. H., Sonpavde, G., Haddad, R. I., Mouw, K. W., Giannakis, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0575 · Cited by 124
Self-citationCan immunostimulatory agents enhance the abscopal effect of radiotherapy?
Lévy, A., Chargari, C., Marabelle, A., Perfettini, J., Magné, N., & Deutsch, É. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.067 · Cited by 122
Prasad, V. K., & Kaestner, V. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.007 · Cited by 121
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
